Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country
ImmunoTargets and Therapy · 2024-09 · Volume 13 · 501-512
DOI: 10.2147/itt.s479153 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoTargets and Therapy, 2024-09. Verfasst von Hikmat Abdel-Razeq und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Hematology and Medical Oncology, King Hussein Cancer Center, Amman, Jordan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Section of Hematology and Medical Oncology, King Hussein Cancer Center, Amman, Jordan.
- School of Medicine, the University of Jordan, Amman, Jordan.
- Office of Scientific Affairs and Research. King Hussein Cancer Center, Amman, Jordan.
ORCID-Profile: Hikmat Abdel-Razeq, Baha Sharaf, Huda Jafar Baidoun, Ayat Taqash, Osama El Khatib, Sarah Edaily, Mahmoud Abunasser, Faris Tamimi
Zitieren
APA
Abdel-Razeq, H., Sharaf, B., Khater, S., Baidoun, H. J., Bani Hani, H., Taqash, A., El Khatib, O., Edaily, S., Abunasser, M., Tamimi, F., Al-Masri, Y. N., Al-Batsh, T. M. W., Zayed, A., Ghatasheh, T., & Radaideh, T. (2024). Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country. ImmunoTargets and Therapy, Volume 13, 501-512. https://doi.org/10.2147/itt.s479153
Vancouver
Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, et al. Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country. ImmunoTargets and Therapy. 2024;Volume 13:501-512. doi:10.2147/itt.s479153
BibTeX
@article{AbdelRazeq2024,
author = {Abdel-Razeq, Hikmat and Sharaf, Baha and Khater, Suhaib and Baidoun, Huda Jafar and Bani Hani, Hira and Taqash, Ayat and El Khatib, Osama and Edaily, Sarah and Abunasser, Mahmoud and Tamimi, Faris and Al-Masri, Yosra Nabeel and Al-Batsh, Tamer Moh'd Waleed and Zayed, Anas and Ghatasheh, Tala and Radaideh, Tala},
title = {Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country},
journal = {ImmunoTargets and Therapy},
year = {2024},
volume = {Volume 13},
pages = {501--512},
doi = {10.2147/itt.s479153}
}
EUVIMED